Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2023 01:25 ET | Source: Novartis Pharma AG

Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements

Ad hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong...
September 05, 2023 01:25 ET | Source: Novartis Pharma AG

Sandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023

Ad-hoc-Mitteilung gemäss Art. 53 LRNachtrag von Sandoz veröffentlicht vor der ausserordentlichen Generalversammlung von Novartis am 15. September 2023Die Ergebnisse des ersten...
August 28, 2023 08:15 ET | Source: Novartis Pharma AG

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years...
August 28, 2023 01:15 ET | Source: Novartis Pharma AG

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly...
August 25, 2023 01:15 ET | Source: Novartis Pharma AG

Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

Biosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients...
August 18, 2023 01:25 ET | Source: Novartis Pharma AG

Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission

Annonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée aux...
August 18, 2023 01:25 ET | Source: Novartis Pharma AG

Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off

Ad-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz...
August 18, 2023 01:25 ET | Source: Novartis Pharma AG

Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote

Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus...
August 15, 2023 01:15 ET | Source: Novartis Pharma AG

Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept

Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading...
August 11, 2023 11:30 ET | Source: Novartis Pharma AG

Novartis completes acquisition of Chinook Therapeutics

Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A...